We are thrilled to have you on our site. If you enjoy the post you have just found kindly Share it with friends.
The Augsburger Allgemeine newspaper quoted a spokeswoman for the company as saying that the German company CureVac expects European approval for its COVID-19 vaccine in June at the latest and is working to increase production capacity.
Since it began in 2000, the biotech company has focused on so-called messenger RNA (mRNA), a drug and vaccine technology that has also become the final focus of procurement negotiations in the European Union.
The mRNA approach has been validated through the widespread use of coronavirus vaccines developed by BioNTech pioneers and its partner Pfizer, as well as by Moderna, in Europe and North America.
But more volumes will be needed to enhance delayed immunization coverage in Europe and possibly for repeated booster doses.
“We hope for approval during the second quarter,” the newspaper quoted the spokeswoman as saying in comments published on Sunday. “We are working to increase production capacity through a growing network of partners.”
The Nasdaq-listed company, backed by investor Dietmar Hope, GlaxoSmithKline as well as the German government, has said it aims to produce up to 300 million doses of the vaccine in 2021 and up to one billion in 2022.
Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of Algulf.net and Algulf.net does not assume any responsibility or liability for the same.